Head, Neck Cancer Time to Treatment Increasing

Share this content:
Time to treatment initiation is rising for patients with head and neck squamous cell carcinoma
Time to treatment initiation is rising for patients with head and neck squamous cell carcinoma

Time to treatment initiation (TTI) is rising for patients with head and neck squamous cell carcinoma, according to a study published online in Cancer.

Colin T. Murphy, M.D., from the Fox Chase Cancer Center in Philadelphia, and colleagues analyzed data from the National Cancer Database to identify head and neck cancer sites (oral tongue, oropharynx, larynx, and hypopharynx) and to determine TTI (the number of days from diagnosis to the initiation of definitive treatment).

The researchers found that based on 274,630 patients from 1998 to 2011, the median TTI for all patients was 26 days, and increased from 19 to 30 days (P < 0.0001). Increased TTI was associated with treatment with chemoradiation (CRT; P < 0.0001), treatment at an academic facility (P < 0.0001), and stage IV disease (P < 0.0001).

RELATED: Study: H. Pylori May Not Be Risk Factor for Head and Neck Cancer

For each disease stage (P < 0.0001), treatment modality (P < 0.0001), and facility type (P < 0.0001), TTI significantly increased over time. Longer TTI was predicted in multivariate analysis by treatment at an academic facility (33 days), transitioning care (37 days), and receipt of CRT (39 days).

"Those who have advanced-stage disease, receive treatment with CRT, are treated at academic facilities, and who have a transition in care realized the greatest increases in TTI," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Reference

  1. Murphy, Colin T., MD, et al. "Increasing time to treatment initiation for head and neck cancer: An analysis of the National Cancer Database." Cancer. DOI: 10.1002/cncr.29191. December 9, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters